|
Título:
|
Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression: Treatment and Diagnostic Implications
|
|
Autores:
|
Veldic, Marin ;
Ahmed, Ahmed T. ;
Blacker, Caren J. ;
Geske, Jennifer R. ;
Biernacka, Joanna M. ;
Borreggine, Kristin L. ;
Moore, Katherine M. ;
Prieto, Miguel L. ;
Vande Voort, Jennifer L. ;
Croarkin, Paul E. ;
Hoberg, Astrid A. ;
Kung, Simon ;
Alarcon, Renato D. ;
Keeth, Nicola ;
Singh, Balwinder ;
Bobo, William V. ;
Frye, Mark A.
|
|
Tipo de documento:
|
texto impreso
|
|
Editorial:
|
Frontiers Media, 2019-07-04T16:59:27Z
|
|
Nota general:
|
info:eu-repo/semantics/restrictedAccess
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
|
|
Idiomas:
|
Inglés
|
|
Palabras clave:
|
Editados por otras instituciones
,
Artículos
,
Artículos en revistas indizadas
|
|
Resumen:
|
Background: Pharmacogenomic testing, specifically for pharmacokinetic (PK) and pharmacodynamic (PD) genetic variation, may contribute to a better understanding of baseline genetic differences in patients seeking treatment for depression, which may further impact clinical antidepressant treatment recommendations. This study evaluated PK and PD genetic variation and the clinical use of such testing in treatment seeking patients with bipolar disorder (BP) and major depressive disorder (MDD) and history of multiple drug failures/treatment resistance. Methods: Consecutive depressed patients evaluated at the Mayo Clinic Depression Center over a 10-year study time frame (2003-2013) were included in this retrospective analysis. Diagnoses of BP or MDD were confirmed using a semi-structured diagnostic interview. Clinical rating scales included the Hamilton Rating Scale for Depression (HRSD24), Generalized Anxiety Disorder
|
|
En línea:
|
http://doi.org/10.3389/fphar.2019.00083
|
